itacitinib (INCB039110) / Incyte, Innovent Biologics  >>  Phase 2
Welcome,         Profile    Billing    Logout  

21 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
itacitinib (INCB039110) / Incyte
2019-003430-16: Safety and efficacy of itacitinib in adults with systemic sclerosis Tolérance et efficacité de l’itacitinib dans la sclérodermie systémique

Not yet recruiting
2
74
Europe
Itacitinib, INCB039110, Tablet
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), Ministry of Health
Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening Patients présentant une sclérodermie systémique (ScS) diffuse nouvellement diagnostiquée ou active au moment de l’évaluation initiale, Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening Patients présentant une sclérodermie systémique (ScS) diffuse nouvellement diagnostiquée ou active au moment de l’évaluation initiale, Diseases [C] - Immune System Diseases [C20]
 
 
2017-005109-11: A study evaluating the impact of Itacitinib alone or when added to ruxolitinib for the treatment of myelofibrosis

Not yet recruiting
2
42
Europe
Itacitinib, INCB039110, Modified-release tablet
Incyte Corporation, Incyte Corporation
Myelofibrosis, Myelofibrosis, Diseases [C] - Cancer [C04]
 
 
2021-000407-20: Treatment of nonsevere sporadic Hemophagocytosis Lymphohistiocytosis (HLHs) with ITACITINIB: a phase II prospective trial.

Not yet recruiting
2
63
Europe
Itacitinib, Tablet
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INCYTE BIOSCIENCES INTERNATIONAL SARL Company,
Adults patients having non severe sporadic Hemophagocytosis Lymphohistiocytosis, Adults patients having non severe sporadic Hemophagocytosis Lymphohistiocytosis, Diseases [C] - Immune System Diseases [C20]
 
 
FLIGHT, NCT04446182: Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD

Hourglass Jul 2022 - Dec 2022 : Data from part-1 of P2 FLIGHT trial for cGVHD
Terminated
2
3
US
Itacitinib, INCB039110, Extracorporeal Photopheresis (ECP), ECP
University of Utah, Incyte Corporation
Chronic Graft-versus-host-disease
03/22
01/23
INCB 39110-211, NCT04071366: A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Completed
2
112
US
Itacitinib, INCB039110, Immune effector cell therapy, CAR-T cell therapy, Placebo, Yescarta, axicabtagene ciloleucel KTE-C19
Incyte Corporation
Cytokine Release Syndrome
02/23
08/23
NCT04339101: Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

Active, not recruiting
2
59
US
Fludarabine, Fluradosa, Itacitinib Adipate, INCB-039110 Adipate, INCB039110 Adipate, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine nitrogen mustard, Sarcoclorin, Sarkolysin, WR-19813, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Sirolimus, AY 22989, RAPA, Rapamune, rapamycin, SILA 9268A, WY-090217, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis
05/23
12/24
NCT04200365: A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)

Terminated
2
15
US
Itacitinib, INCB039110 adipate
SCRI Development Innovations, LLC, Incyte Corporation
Chronic Graft-versus-host-disease
09/23
09/23
HLH-JAK, NCT05063110: Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB

Recruiting
2
63
Europe
Itacitinib
Assistance Publique - Hôpitaux de Paris, Incyte Corporation
Adults Patients Having Non Severe HLH
11/23
02/24
NCI-2022-03765, NCT05364762: Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

Recruiting
2
50
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Itacitinib, INCB 039110, INCB-039110, INCB039110, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Quality-of-Life Assessment, Quality of Life Assessment, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
04/24
04/24
NCT04509700: Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Recruiting
2
200
Europe, Japan, US, RoW
Parsaclisib, INCB050465, parsaclisib + itacitinib, INCB39110, parsaclisib + ruxolitinib, INCB018424, parsaclisib + ibrutinib
Incyte Corporation
B-Cell Malignancies
09/24
09/24
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
NCT05660421: Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Recruiting
2
25
US
Itacitinib, Corticosteroid, Endoscopic Procedure, Skin biopsy, Biospecimen Collection
Douglas Johnson, Incyte Corporation
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
04/26
04/27
SCLERITA, NCT04789850: Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis

Recruiting
2
74
Europe
Itacitinib, Placebo
Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis
02/26
02/26
NCT04640025: A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib

Active, not recruiting
2
18
Europe, Canada, US, RoW
itacitinib, INCB039110
Incyte Corporation
Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host Disease
06/26
06/26
NCT05757219: Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Recruiting
2
27
US
Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy, YESCARTA, Axi-cel
H. Lee Moffitt Cancer Center and Research Institute, Incyte Corporation
Diffuse Large B Cell Lymphoma
10/24
11/26
2022-001076-34: The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes ABNL-MARRO 001: Un estudio de fase I/II de combinaciones de compuestos con diana mieloide activa en síndromes mixtos SMD/NMP del tejido conjuntivo

Not yet recruiting
1/2
117
Europe
ASTX727, Itacitinib, Tablet
Theradex (Europe) Ltd., Vanderbilt University Medical Center, Incyte Corporation, Astex Pharmaceuticals
Myelodysplastic syndrome/Myeloproliferative Neoplasm Overlap Syndromes Síndromes de superposición mielodisplasia/neoplasia mieloproliferativa, Myelodysplastic syndrome/Myeloproliferative Neoplasm Overlap Syndromes Síndromes de superposición mielodisplasia/neoplasia mieloproliferativa, Diseases [C] - Cancer [C04]
 
 
NCT03978637: Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

Terminated
1/2
23
Europe, Canada, US
Itacitinib, INCB039110
Incyte Corporation
Bronchiolitis Obliterans Syndrome
10/23
10/23
2019-004171-39: A Study evaluating the safety and efficacy of Itacitinib in participants with bronchiolitis obliterans syndrome following lung Transplantation

Not yet recruiting
1/2
79
Europe
itacitinib, INCB039110, Prolonged-release tablet
Incyte Corporation, Incyte Corporation
Bronchiolitis Obliterans Syndrome following Lung Transplantation, Bronchiolitis Obliterans Syndrome following Lung Transplantation, Diseases [C] - Immune System Diseases [C20]
 
 
NCT02917993 / 2017-001750-34: An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Active, not recruiting
1/2
59
Europe, US, RoW
Itacitinib, INCB039110, Osimertinib
Incyte Corporation, AstraZeneca
Lung Cancer
12/25
12/25
ABNL-MARRO, NCT04061421: Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes

Recruiting
1/2
105
US
ASTX727, Fixed dose combination of cedazuridine (100mg) + oral decitabine (35mg), Itacitinib, INCB039110
Michael Savona, Incyte Corporation, Theradex, Astex Pharmaceuticals, Inc.
MDS/MPN
08/24
08/25
NCT03697408: Itacitinib + Everolimus in Hodgkin Lymphoma

Active, not recruiting
1/2
23
US
Itacitinib, INCB039110, Everolimus, Afinitor
University of Pennsylvania
Classical Hodgkin Lymphoma
10/24
06/27

Download Options